Fannie Mae, Freddie Mac shares tumble after conservatorship comments
On Tuesday, Canaccord Genuity analysts raised their price target for Taysha Gene Therapies stock to $11 from a previous target of $9, while keeping a Buy rating. According to InvestingPro data, this new target represents significant upside potential from the current price of $2.79, with analyst targets ranging from $5 to $11. The change follows updates to the analysts’ model for Taysha Gene Therapies, including an increased probability of success for TSHA-102 and a $200 million offering through a combination of shares and prefunded warrants.
The analysts noted that the probability of success for TSHA-102 has been increased to 75% from the previous 50%. This adjustment reflects the firm’s updated assessment of the therapy’s potential in the market.
Taysha Gene Therapies recently announced a $200 million offering that includes a mix of shares and prefunded warrants. This financial move is part of the company’s strategy to support its ongoing development projects and operations.
The revised price target and maintained Buy rating indicate the analysts’ confidence in the company’s growth prospects and its strategic initiatives. Taysha Gene Therapies continues to focus on advancing its gene therapy pipeline to address unmet medical needs.
Shares of Taysha Gene Therapies are traded on the NASDAQ under the ticker TSHA.
In other recent news, Taysha Gene Therapies announced that its stockholders approved an amendment to increase the authorized number of common stock shares from 400 million to 700 million. This decision was made during the company’s 2025 annual meeting, where two directors were also elected, and Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year. Additionally, Cantor Fitzgerald maintained an Overweight rating on Taysha Gene Therapies with a price target of $7.00, citing confidence in the company’s gene therapy developments for Rett syndrome. The company unveiled details of a pivotal trial design for TSHA-102, receiving positive feedback from the FDA, which will allow a single-arm, open-label pivotal trial to proceed. JMP Securities also increased its price target on Taysha to $6.00, highlighting the strong clinical data and FDA alignment. Furthermore, Taysha announced a public offering of its common stock and pre-funded warrants, managed by Jefferies, BofA Securities, Piper Sandler, and Barclays (LON:BARC). These developments underscore Taysha’s progress in advancing its gene therapy pipeline and addressing severe monogenic diseases of the central nervous system.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.